Detection of Esophageal Cancer by Assay of Novel Methylated DNA Markers in Plasma

Overview

About this study

The purpose of the study is to see if the plasma assay of MDMs using optimized markers and analytically sensitive assays will detect early-stage esophageal cancer at high specificity.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Please contact the study team to discuss whether or not you are eligible to participate in a study.

Inclusion Criteria:

Cases:

  • Consent for study
  • >3 mL single spun plasma available
  • Esophageal adenocarcinoma or Esophageal squamous cell carcinoma diagnosed by biopsy of the primary lesion, or by biopsy of lymph node or distant metastasis

Controls:

  • Consent for study
  • >3 mL single spun plasma available

 

Exclusion Criteria:

Cases:

  • Known primary cancer outside of the esophagus, detected within 5 years prior to collection, and within 3 years after, excluding basal cell or squamous skin cancers.
  • Prior chemotherapy class drugs or radiation for the primary esophageal cancer
  • Biopsy/endoscopic/surgical treatment with intent to remove or de-bulk the primary lesion prior to stool and plasma collection
  • Age <18

Controls:

  • History of esophageal cancer (squamous or adenocarcinoma)
  • Known primary cancer outside of the esophagus, detected within 5 years prior to collection, and within 3 years after, excluding skin cancers
  • Age <18
  • Diagnosis of Familial cancer syndromes such as HPNCC and FAP

Stool-specific, for both controls and cases:

  • Bowel prep <7 days prior to stool collection
  • Removal of >50% of colon or presence of ileostomy
  • Enteral feeds or TPN
  • Diagnosis of inflammatory bowel disease.
  • Pre-cancerous polyps or cancer found at baseline study colonoscopy
  • Diagnosis of Familial cancer syndromes such as HPNCC and FAP
  • Enteric barium studies within the prior 7 days before stool collection

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

John Kisiel, M.D.

Open for enrollment

Contact information:

Kari Lowrie

(507)266-3778

Lowrie.Kari@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

Additional contact information

Cancer-related trials contact form

Phone: 855-776-0015 (toll-free)

International patient clinical studies questions